The cumulative incidence of strokes at 3-year follow-up was 15.7 % in TAVR patients versus 5.5 % in patients undergoing standard therapy ( hazard ratio , 2.81 ; 95 % confidence interval , 1.26-6 .26 ; P = 0.012 ) ; however , the composite of death or strokes was significantly lower after TAVR versus standard therapy ( 57.4 % versus 80.9 % , P < 0.001 ; hazard ratio , 0.60 ; 95 % confidence interval , 0.46-0 .77 ; P < 0.001 ) .